Incyte Corporation (INCY)
INCYNASDAQ-GSBiotechnology: Commercial Physical & Biological Resarch
$119.63
-2.26 (-1.85%) today
Regular session, Nov 10, 2:44 PM ET
- Market cap
- $24.40bn
- P/E
- 56.4
- EPS, last 4 quarters
- $2.12
- Dividend yield
- –
- Day range
- $119.03 to $121.25
- 52-week range
- $89.25 to $132.60
- Average volume
- 1.70m
- Previous close
- $121.89
Analysts
19 coveringHold10 buy, 9 hold, 0 sell
Targets a year out average $134.37, +12.3% from here
Earnings
next estimate $1.61Next report
Dec 2025
-4.9%
Mar 2026
+36.0%
Jun 2026
+59.1%
Sep 2026
+11.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.51bn | $1.27bn | $1.67bn | $1.56bn |
| Gross profit | $1.39bn | $1.17bn | $1.57bn | $1.45bn |
| Operating income | $335.86m | $301.12m | $697.90m | -$708.36m |
| Net income | $299.28m | $303.33m | $585.61m | -$784.80m |
Last four quarters: revenue $6.01bn, margin 6.7%, free cash flow $684.87m
News
8 latest- China Medical System: Singapore's HSA Clears Lumirix, First Topical Rx Drug For Vitiligo Treatment RTTNews · 7 days ago
- Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo Growth RTTNews · Nov 3, 2026
- Incyte (INCY) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- What Incyte (INCY) Said on Its Q3 Earnings CallMarketBeat · Oct 29, 2026
- INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedZacks · Oct 29, 2026
- Incyte Posts Q3 Loss On $1.23 Bln Vega Acquisition Charge; Raises FY26 Sales Outlook RTTNews · Oct 29, 2026
- Incyte Corporation Reports Third Quarter 2026 Total Revenue of $1.56 billionFintel · Oct 29, 2026
- Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to SayZacks · Oct 29, 2026
The company
Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- incyte.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.